Literature DB >> 1394204

Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats.

O Cay1, M Radnell, B Jeppsson, B Ahrén, S Bengmark.   

Abstract

Since tumor cells are more dependent on glycolysis for energy supply than other cells, we tested whether its inhibition by 2-deoxy-D-glucose (2-DG) affects tumor growth. Male Wistar rats were inoculated in the liver with tumor cells from a chemically induced colonic adenocarcinoma. From day 5 after inoculation 2-DG (400 mg/kg/24 h) was continuously infused into the hepatic artery for 5 days; controls received saline in the same fashion. Seven days after the end of infusion, the animals were sacrificed. A second experimental group of rats was treated with isolated liver perfusion for 30 min with oxygenated blood through the portal vein and hepatic artery simultaneously. In the perfusate, 400 mg/kg 2-DG were added, and the rats were sacrificed at 10 days after perfusion. A first control group underwent perfusion without 2-DG, and a second control group received i.v. infusion of 2-DG (400 mg/kg/30 min) for 30 min over 5 days. A nontreated control group was also added. All animals survived the procedures. The concentration of blood glucose increased in the rats receiving 2-DG i.v. and intraarterially but was unchanged in the other groups. The tumor growth was significantly reduced by 2-DG in all experimental groups, with no difference between the groups. It is therefore concluded that 2-DG is of potential interest in the treatment of malignancies. Since local application of 2-DG avoids the risk for systemic side effects, this approach should be explored further.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1.

Authors:  Shikha Khatri; Hasmik Yepiskoposyan; Catherine A Gallo; Preeti Tandon; David R Plas
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

2.  2-Deoxyglucose impairs Saccharomyces cerevisiae growth by stimulating Snf1-regulated and α-arrestin-mediated trafficking of hexose transporters 1 and 3.

Authors:  Allyson F O'Donnell; Rhonda R McCartney; Dakshayini G Chandrashekarappa; Bob B Zhang; Jeremy Thorner; Martin C Schmidt
Journal:  Mol Cell Biol       Date:  2014-12-29       Impact factor: 4.272

3.  Laforin confers cancer resistance to energy deprivation-induced apoptosis.

Authors:  Yin Wang; Yan Liu; Cindy Wu; Beth McNally; Yang Liu; Pan Zheng
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 4.  Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.

Authors:  Chih-Chien Chou; Santosh B Salunke; Samuel K Kulp; Ching-Shih Chen
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

5.  Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth.

Authors:  Gregor Beuster; Kim Zarse; Christoph Kaleta; René Thierbach; Michael Kiehntopf; Pablo Steinberg; Stefan Schuster; Michael Ristow
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

6.  Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet.

Authors:  Jeremy Marsh; Purna Mukherjee; Thomas N Seyfried
Journal:  Nutr Metab (Lond)       Date:  2008-11-25       Impact factor: 4.169

7.  New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.

Authors:  Eva Gottfried; Sven A Lang; Kathrin Renner; Anja Bosserhoff; Wolfram Gronwald; Michael Rehli; Sabine Einhell; Isabel Gedig; Katrin Singer; Anton Seilbeck; Andreas Mackensen; Oliver Grauer; Peter Hau; Katja Dettmer; Reinhard Andreesen; Peter J Oefner; Marina Kreutz
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

Review 8.  Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy.

Authors:  Hyun Jung Kee; Jae-Ho Cheong
Journal:  BMB Rep       Date:  2014-03       Impact factor: 4.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.